Emergent Biosolutions
EBS
183 hedge funds and large institutions have $537M invested in Emergent Biosolutions in 2025 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 60 increasing their positions, 52 reducing their positions, and 25 closing their positions.
245% more call options, than puts
Call options by funds: $7.82M | Put options by funds: $2.27M
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
52% more capital invested
Capital invested by funds: $352M → $537M (+$184M)
15% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 52
8% more funds holding
Funds holding: 169 → 183 (+14)
4.5% more ownership
Funds ownership: 78.16% → 82.65% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.74M |
| 2 |
JG
Jain Global
New York
|
+$4.65M |
| 3 |
D.E. Shaw & Co
New York
|
+$4.31M |
| 4 |
Jane Street
New York
|
+$4.24M |
| 5 |
HF
HRT Financial
New York
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$4.73M |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$3.8M |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$2.91M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$2.41M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.87M |
EBS Hedge Fund Activity: Q4 2025 in Review
183 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2025, worth a combined $537M — up 52% from $352M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new EBS positions and 25 closed out — a net gain of 17 holders — while 60 added to existing stakes and 52 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.74M. The largest seller was Pacer Advisors, exiting entirely with an estimated $4.73M sold.
- 183 institutional investors held Emergent Biosolutions (EBS) as of Q4 2025, up from 169 in Q3 2025.
- Funds reported $537M of Emergent Biosolutions stock for Q4 2025, up 52% quarter-over-quarter.
- 42 funds opened new Emergent Biosolutions positions in Q4 2025 and 25 closed out, a net change of +17 holders.
- The largest Emergent Biosolutions buyer in Q4 2025 was Morgan Stanley, an estimated $6.74M added.
- The largest Emergent Biosolutions seller in Q4 2025 was Pacer Advisors, an estimated $4.73M sold.
Based on aggregated 13F filings for Q4 2025.